Moreover, treatment of Btk–/– mice with GM-CSF conferred a significant survival benefit after aspergillosis relative to Btk–/– mice that did not receive GM-CSF (survival, 79% versus 42%, respectively) (Figure 7I). This evidence concerns the gene CSF2 and aspergillosis.